The issue of drug lags and losses and the review of health coverage are Japan’s “national challenge,” and all stakeholders should rally around the goal of addressing these issues, EFPIA Japan Chair Takahiko Iwaya said on October 9. Iwaya made…
To read the full story
Related Article
- EFPIA Japan Issues Joint Statement for Resolving Drug Lags/Losses
December 12, 2024
ORGANIZATION
- Labor Group Chief Pushes Fundamental Drug Pricing Reform Ahead of Honebuto
April 8, 2026
- Drug Makers Step Up Self-Inspections for Supply Stability: FPMAJ Survey
April 8, 2026
- Pharma Labor Group Sees Wage Hikes in Low 4% Range as Talks Continue
April 7, 2026
- Generic Use Rate Hits 90% for First Time in October-December: JGA
April 7, 2026
- JPMA to Prepare Response to US “MFN” Policy under New Strategy Unit
April 2, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





